Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Insect Venom

PreclinicalSmall molecule

MMedical University of Graz

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnaphylaxisActive, not recruiting

AnaphylaxisPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q1 2029

Bee Venom

NCT04259359

Clinical

Trials by Indication[1]

Anaphylaxis1 trial

The Effect of Antihypertensive Drugs on Severity of Anaphylaxis and Side-effects During Venom Immunotherapy

Completed·MMedical University of Graz··NCT04269629·1,425 enrolled

Bee Venom1 trial

Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure

Recruiting·MMedical University of Graz··NCT04259359·266 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Insect Venom. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insect Venom compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insect Venom. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Graz

Related News